PV Bulletin

PSUSA/00000414/202601 - periodic safety update report single assessment

Periodic safety update report single assessments (PSUSAs) are single assessments of related periodic safety update reports (PSURs) for active substances contained in medicines authorised in the European Union (EU).

Primary source: Website data protection notice

Translated From French

PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.

PV Impact Brief

Urgency: HighConfidence: high

What changed

A new periodic safety update report single assessment for biotin has been published, impacting the reporting requirements for associated medicinal products.

Why it matters

This PSUSA may necessitate updates to pharmacovigilance practices and signal management processes to ensure compliance with the new reporting obligations.

Action needed

Regulatory intelligence should be updated to reflect the new PSUSA, and signal management processes may require reviews based on new safety information.

Relevant for
PV Quality Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Sep 3, 2026

Full briefing

Practical implication

Regulatory intelligence should be updated to reflect the new PSUSA, and signal management processes may require reviews based on new safety information.

The European Medicines Agency (EMA) has published a new periodic safety update report single assessment (PSUSA/00000414/202601) concerning the active substance biotin, outlining the implications for related medicinal products authorized in the EU.

What changed: A new periodic safety update report single assessment for biotin has been published, impacting the reporting requirements for associated medicinal products.

Why it matters: This PSUSA may necessitate updates to pharmacovigilance practices and signal management processes to ensure compliance with the new reporting obligations.

Practical implication: Regulatory intelligence should be updated to reflect the new PSUSA, and signal management processes may require reviews based on new safety information.

View original source

  • Source: EMA - What's new RSS
  • Published at source: 2026-09-03T00:00:00.000Z
  • Discovered by monitor: 2026-09-03T21:46:08.709Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signals#Translated From French#European Union#Ema.europa.eu#Reporting Requirement#Source-ingestion#Regulator-monitor

Related updates for your role

publicFDA · USA · Updated Sep 3, 2026

FDA Issues Emergency Use Authorization for Drugs to Prevent and Treat New World Screwworm in Dogs and Cats

Urgency: High

Update product labels to include prevention indications for Capstar and Nitenpyram Tablets. Ensure that labeling reflects new usage guidelines for these products as outlined in the Emergency Use Authorization.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 3, 2026Translated From French

Eyefill C Viscoelastic Product Recall - Bausch & Lomb

Urgency: High

Healthcare establishments must quarantine the affected Eyefill C lots, refrain from using them, and monitor patients who received the device.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 3, 2026Translated From French

Carestation 850 and 850c Anesthesia Systems Safety Notification

Urgency: High

Users must ensure systems remain connected to power, conduct proper startup procedures, perform preoperative checks, and have emergency ventilation plans in place. Acknowledgment of receipt of the safety notice is required within 30 days.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 3, 2026Translated From French

MAS Omni Immune Pro Reagent – Microgenics Corporation, Thermo Fisher Scientific

Urgency: High

Users are required to monitor inventory for affected lots and comply with instructions for potential disposal according to updated guidance from Microgenics Corporation.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward